Citation Impact
Citing Papers
T-cell exhaustion in the tumor microenvironment
2015
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
2015
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
2020
Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey
2020 Standout
Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer
2015
mTOR Signaling in Growth Control and Disease
2012 Standout
A view on drug resistance in cancer
2019 StandoutNature
The biology and management of non-small cell lung cancer
2018 StandoutNature
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Macrophages in immunoregulation and therapeutics
2023 Standout
mTOR signaling and drug development in cancer
2010
Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: A beneficial strategy to combat non-small cell lung cancer
2011
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Lung cancer: New biological insights and recent therapeutic advances
2011
Lung cancer: current therapies and new targeted treatments
2016 Standout
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
2015
Histology-agnostic drug development — considering issues beyond the tissue
2020
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
2012
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
2020 Standout
Autophagy modulation as a potential therapeutic target for diverse diseases
2012 Standout
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
2012
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms
2017
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Management of glioblastoma: State of the art and future directions
2020 Standout
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
2015
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
2011
Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity
2015
Multi-targeted therapy of cancer by niclosamide: A new application for an old drug
2014 Standout
Role of Personalized Nutrition in Chronic-Degenerative Diseases
2019
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
2023 StandoutNobel
Works of J. Wolf being referenced
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
2009
Histone modifications and their role in epigenetics of atopy and allergic diseases
2018
Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
2014
Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study
2014
Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
2018